DPYD, TYMS, TYMP, TK1, and TK2 Genetic Expressions as Response Markers in Locally Advanced Rectal Cancer Patients Treated with Fluoropyrimidine-Based Chemoradiotherapy

 

Ming-Yii Huang,1,2,3 Chan-Han Wu,4 Chun-Ming Huang,1,2

Fu-Yen Chung,4 Ching-Wen Huang,5,6,7 Hsiang-Lin Tsai,3,5,8 Chin-Fan Chen,9

Shiu-Ru Lin,4 and Jaw-Yuan Wang3,5,6,9,10,11

 

Received 6 November 2013; Accepted 22 November 2013

 

Abstract:This study is to investigate multiple chemotherapeutic agent- and radiation-related genetic biomarkers in locally advanced rectal cancer (LARC) patients following fluoropyrimidine-based concurrent chemoradiotherapy (CCRT) for response prediction. We initially selected 6 fluoropyrimidine metabolism-related genes (DPYD, ORPT, TYMS, TYMP, TK1, and TK2) and 3 radiotherapy response-related genes (GLUT1, HIF-1